Herbst Kinsky has advised Ribbon Biolabs on its EUR 18 million Series A financing round. Brandl Talos advised lead investor Hadean Ventures.
Existing investors Lansdowne Partners, Helicase Venture, IST Cube, and Tecnet Equity also participated in the financing round.
According to Herbst Kinsky, "the company intends to use the new capital to commercialize its DNA synthesis technology, which integrates combinatorial optimization algorithms to guide the automated enzymatic assembly of DNA."
Founded in 2018 in Vienna, biotech start-up Ribbon Biolabs is a synthetic biology company, focusing on subgenomic size synthetic DNA as a component for development in biopharmaceutical research.
Hadean Ventures is a European life science venture capital fund manager with around EUR 200 million in assets under management.
"Synthetic biology is about to disrupt the biopharmaceutical and other life science industries by overcoming previous limitations with new genetic technologies," Hadean Ventures Managing Partner Walter Stockinger commented. "We are excited to support Ribbon Biolabs in its mission to fully automate long DNA synthesis through its novel and proprietary approach and to become an important player in this new field of biology."
The Herbst Kinsky team was led by Partner Philipp Kinsky and Attorney-at-Law Carl Walderdorff and included Attorney-at-Law Christina Bernhart.
The Brandl Talos team was led by Partner Roman Rericha and included Attorney-at-Law Stephan Strass and Associates Elena Ciresa and Celine Dobnikar.
